Concor AM is generally used to help manage symptoms and ease the overall burden of symptoms in certain cardiovascular conditions. This fixed-dose combination is commonly used across conditions presenting with episodic or fluctuating symptom patterns associated with elevated blood pressure and chest discomfort. It provides support that helps ease the overall burden of symptoms.

---

Symptomatic Blood Pressure Control

This therapeutic domain is applied in areas where short-term symptom management is appropriate for symptoms related to systemic imbalance that create noticeable physiological strain from elevated pressure. Concor AM is commonly used to help address symptom clusters that may become intense or disruptive, providing supportive relief that helps patients cope more steadily with symptom fluctuations.

---

Reducing Cardiovascular Strain

The medicine is applied across domains where additional symptomatic support is needed to ease the overall symptom load and systemic burden. It is relevant in conditions characterized by periods of heightened physiological activity, assisting with maintaining functional stability, which supports general well-being during symptomatic phases.

---

Quick Fact: Supports in easing Physiological Strain

---

Long-Term Vascular Protection

This area focuses on supportive relief in the context of chronic condition management. The treatment is considered relevant in clinical settings marked by temporary physiological imbalance, contributing to improved comfort and assists with maintaining functional stability, and is used in areas where short-term symptom management is appropriate to ease the overall symptom load on the vascular system.

Regulatory References

1. Philippine FDA Summary of Indications

Who Can and Cannot Use Concor AM?

The eligibility for Concor AM is strictly defined by regulatory guidelines, primarily restricting its use to certain populations and contraindicating it in others based on the known effects of its components (Amlodipine and Bisoprolol Fumarate).

---

Populations for Permitted and Restricted Use

• Adults (ge 18 years): The medicine is indicated only as substitution therapy for adults whose blood pressure is already adequately controlled by the individual components taken separately.
• Pediatric Population (mathbf< 18 years): Use is not recommended, as safety and efficacy have not been established in this age group.
• Pregnancy and Lactation: Use is generally not recommended.
• Severe Organ Impairment: Patients with severe renal impairment or severe hepatic impairment require conditional use, often involving an explicit dose limitation on the Bisoprolol component.

---

Absolute Contraindications (Must Not Use)

Concor AM is prohibited for individuals with conditions including, but not limited to:

• Acute Heart Failure or Cardiogenic Shock.
• Second or Third Degree AV Block (without a pacemaker).
• Severe Symptomatic Hypotension or Symptomatic Bradycardia.
• Severe Bronchial Asthma or severe obstructive airway disease.
• Known hypersensitivity to the active ingredients or other dihydropyridine derivatives.
• Severe Aortic Stenosis or obstruction of the left ventricular outflow tract.

Interactions with other medicines and products

The official regulatory documents specify distinct interaction patterns for the Amlodipine and Bisoprolol fixed-dose combination. Contraindicated combinations include the co-administration of Verapamil or Diltiazem, non-dihydropyridine calcium channel blockers, due to the high risk of severe pharmacodynamic reinforcement that may cause excessive bradycardia or hypotension.

Exposure of the Amlodipine component is subject to pharmacokinetic modification via the CYP3A4 enzyme pathway. Strong or moderate CYP3 A4 inhibitors, such as Itraconazole or Ritonavir, may cause a significant increase in Amlodipine plasma concentrations. Conversely, CYP3 A4 inducers like Rifampicin or the herbal product St. John’s wort may result in lower Amlodipine exposure. The co-administration of Amlodipine with Simvastatin has been documented to result in a 77% increase in Simvastatin exposure.

Specific procedural constraints govern certain combinations. When discontinuing centrally acting antihypertensive agents (e.g., Clonidine), withdrawal must not occur until several days after stopping the Bisoprolol component to mitigate the risk of severe rebound hypertension. Furthermore, consumption of Grapefruit juice is officially not recommended as it may alter Amlodipine bioavailability. Regulatory caution is also noted for patients with severe hepatic impairment, as the prolonged half-life of Amlodipine exacerbates the risk of accumulation from interacting drugs.

Vascular Tone Modulation via Calcium Channel Blockade

Amlodipine's mechanism involves the selective antagonism of Cav1.2 L-type calcium channels found on the membranes of vascular smooth muscle cells. This blockade prevents the necessary influx of extracellular calcium ions, which are essential for muscle contraction. The resulting molecular cascade leads to the relaxation and widening of the blood vessels, thereby reducing the Peripheral Vascular Resistance (PVR).

---

Attenuation of Cardiac Sympathetic Signaling

Bisoprolol Fumarate acts as a highly selective antagonist of beta1-adrenergic receptors, primarily located in the cardiac tissue. By competitively blocking these receptors, it prevents the stimulatory effects of natural catecholamines (stress hormones), dampening the influence of the Sympathetic Nervous System on the heart. The beta1-adrenergic receptor blockade produces negative chronotropy (reduction in heart rate) and negative inotropy (decrease in the force of contraction).

---

Synergistic Hemodynamic Stabilization

The combination utilizes synergy: Bisoprolol's action to reduce heart activity mitigates the reflex tachycardia (speeding up of the heart) that can physiologically occur as a compensatory response to Amlodipine's vasodilation. This integrated mechanism provides a balanced, dual-pathway approach that results in the modulation of systemic pressure by influencing both vascular resistance and cardiac output simultaneously.

Administration Protocol

Concor AM is an oral, fixed-dose combination tablet containing Amlodipine and Bisoprolol, intended for once-daily administration. The medicine is primarily used as substitution therapy in patients whose blood pressure is already controlled on the individual components taken separately. The standard regimen involves taking one tablet of the appropriate strength (e.g., 5 mg/5 mg up to 10 mg/10 mg) once daily.

---

Dosing and Administration Instructions

Instruction Domain	Official Label Statement
Route and Timing	The tablet must be taken orally in the morning.
Food Relationship	Administration is permitted with or without food.
Physical Intake	The tablet should be swallowed whole with fluid, and without chewing.
Tablet Scoring	The score line on the tablet is present only to facilitate ease of swallowing and is not intended for dividing the tablet into equal doses.

---

Procedural Constraints

Official labeling defines specific constraints for its use in certain populations and treatment discontinuation. For patients with severe renal impairment (creatinine clearance < 20 mL/min) or severe hepatic impairment, the daily dose of the Bisoprolol component must not exceed 10 mg. The safety and efficacy of this medicine have not been established in children and adolescents below the age of 18 years.

Treatment must not be stopped abruptly; instead, a gradual decrease in dosage is recommended to prevent the temporary deterioration of a pre-existing clinical condition.

Research evidence / Overview of studies for Concor AM

Evidence for Use in Managing High Blood Pressure

The fixed-dose combination of Amlodipine and Bisoprolol was evaluated in research exploring high blood pressure, specifically in adults whose blood pressure readings were not at goal while receiving single-agent therapy. Research has explored how outcomes monitoring physiological strain change over time in this specific group.

The primary research approach involves short-term Randomized Controlled Trials (RCTs), which compare the fixed-dose combination (FDC) tablet to the individual components (monotherapy) and to the free-dose combination. These studies focus on outcomes monitoring physiological strain by measuring Systolic and Diastolic Blood Pressure (BP) over periods typically lasting around 18 weeks. Studies monitored the proportion of patients whose BP readings met accepted goals during the observation period.

Evaluating the Combination Approach in Studies

Research has explored whether the fixed-dose tablet was associated with different outcomes when compared to the two individual drugs taken separately (the free combination). Bioequivalence studies were designed to investigate whether the FDC tablet delivers the medicine to the body in a similar way to taking two individual tablets at the same time.

A key focus of large observational studies was patient adherence. These studies examined if the fixed-dose delivery was associated with patterns of patients more consistently taking their medication as prescribed. Research highlights changes measured during the study period for adherence, which was monitored using methods like pill counts and patient diaries. This evidence captures patterns observed in the studies regarding consistency of use in daily-life functioning.

Long-Term Data and Extended Follow-up

While numerous studies have explored the short-term physiological measurements of the FDC for blood pressure control, the long-term effects are not fully established specifically for this fixed-dose formulation. Most research studies monitored intermediate measurements, such as readings of BP and Heart Rate, typically over periods of six months to one year.

What is Still Uncertain in the Research

The available evidence quality varies across studies, with many of the largest datasets coming from non-interventional, observational research rather than double-blind controlled trials. The key limitations of the current research include the focus on surrogate measures, such as blood pressure readings, over long-term clinical endpoints. The follow-up durations were limited in the core randomized trials. This means that while research provides insight into short-term changes, research does not determine the full, lifelong impact on major outcomes for the fixed-dose combination.

Key Studies & References

1. Concor AM (Amlodipine/Bisoprolol Fumarate): Philippine FDA Summary of Indications (DR-XY44731)

Common questions about Concor AM (FAQ)

Q: Does Concor AM treat high blood pressure or angina, or both conditions?

A: Regulatory documents describe the medicine's use for the management of high blood pressure (hypertension). The single beta-blocker component (bisoprolol), which is part of this combination, is also indicated in some regions for the treatment of angina pectoris (chest pain) to help reduce the heart's workload.

Q: Can Concor AM affect kidney function over time?

A: Official product information notes that special caution is required when the medicine is used in patients who already have severe renal impairment (severe kidney damage). Guidelines include an explicit dose limitation on the bisoprolol component for this specific patient group.

Q: Is it possible for Concor AM to cause swelling in the ankles or feet?

A: Yes, regulatory labeling states that oedema (swelling) is a common adverse reaction, meaning it may affect up to 1 in 10 people. This is often observed as ankle swelling and is primarily associated with the amlodipine component of the medicine.

Q: Can Concor AM affect men's or women's sexual health?

A: Official labeling for the amlodipine component of this medicine has included sexual dysfunction in both males and females as a reported effect. This is one of the less common effects described in post-marketing experience documents.

Q: If I have low blood pressure already, can I still take Concor AM?

A: According to the official product information, this medicine is contraindicated (prohibited) for individuals who have severe symptomatic hypotension. This refers to very low blood pressure that is causing symptoms.

Q: Does Concor AM interact with common pain relievers like ibuprofen or aspirin?

A: Regulatory documents state that certain Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), such as ibuprofen, may potentially reduce the blood pressure-lowering effect of the bisoprolol component. Information regarding combinations should always be reviewed by a qualified healthcare professional.

Q: Can Concor AM be crushed, split, or chewed?

A: Official administration instructions specify that the tablet must be swallowed whole with fluid and should be taken without chewing. If a score line is present, it is for ease of swallowing and not for dividing the tablet into equal doses.

Q: What is the main difference between Concor AM and just taking Concor alone?

A: Concor AM is a fixed-dose combination product containing two active ingredients: amlodipine (a calcium channel blocker) and bisoprolol (a beta-blocker). The single-ingredient product, Concor, contains only the bisoprolol component. The combination approach is described as a strategy to address blood pressure using two different mechanisms.

Q: Is Concor AM considered a blood thinner, or does it work differently?

A: Regulatory information indicates the medicine is classified as a combination of a calcium channel blocker and a beta-blocker used to lower blood pressure. It is not classified as a blood-thinning medicine.

Q: How long does it usually take to notice the effects of Concor AM?

A: Official documents describe the components as having long half-lives, meaning they stay in the body for an extended period. This design allows for sustained control of blood pressure over a full 24-hour period with once-daily dosing.

Q: If I miss a dose of Concor AM, what should I generally do?

A: If a dose is missed, regulatory instructions suggest taking it as soon as it is remembered. However, if it is almost time for the next scheduled dose, the missed dose should be skipped entirely to avoid taking a double dose.

Q: Are there any specific foods or drinks I should limit while taking this medication?

A: Regulatory information specifically advises that the consumption of Grapefruit juice is not recommended because it may alter the amount of the amlodipine component available in the body. Some documents also suggest limiting alcohol intake.

Q: What other common medicines might interact with Concor AM?

A: Official documents describe interactions with several classes of drugs. These include certain antifungals and antibiotics, other blood pressure medicines (like non-dihydropyridine calcium channel blockers), and Non-Steroidal Anti-Inflammatory Drugs (NSAIDs).

Q: Is there a best time of day to take Concor AM?

A: Regulatory documents specify that the tablet must be taken orally in the morning. It is also generally advised to take the medicine at the same time each day for consistent effect.

Q: What happens to the body if I accidentally take too much Concor AM?

A: Symptoms of overdose described in labeling can include significant effects on the heart and circulation. These may include dizziness, fainting, an unusually slow heartbeat (bradycardia), or a severe drop in blood pressure (hypotension).

Q: How does Concor AM affect physical exercise or high activity levels?

A: The beta-blocker component (bisoprolol) is known to reduce the heart's pumping capacity both at rest and during exercise. This effect is why patients with certain pre-existing conditions may be monitored for signs of exercise intolerance.

Q: Are there any known interactions between Concor AM and herbal supplements?

A: Official documents specifically identify an interaction risk with the herbal product St. John’s wort. This is because it may alter the amount of the amlodipine component available in the body.

Q: Does Concor AM cause changes in mood or anxiety levels?

A: The adverse reaction profile includes reports of changes in the central nervous system, such as depression, sleep disorders, anxiety, and abnormal dreams. These are generally listed as uncommon or less common effects in regulatory documentation.

Q: What is the difference between Concor AM and a medicine like Amlodipine by itself?

A: Concor AM is a fixed-dose combination containing both amlodipine (a calcium channel blocker) and bisoprolol (a beta-blocker). Amlodipine monotherapy contains only the blood vessel-relaxing amlodipine component, but not the bisoprolol component that helps control heart rate.

Q: What is the highest strength of Concor AM available?

A: Official documents list available tablet strengths for the fixed-dose combination, ranging up to 10 mg/10 mg (Amlodipine/Bisoprolol).

Q: Why do some people feel a coldness in their hands and feet while taking Concor AM?

A: A feeling of coldness or numbness in the extremities (hands and feet) is listed as a Common adverse reaction in the official product information. This effect is typically associated with the beta-blocker component.

Q: Are headaches a common side effect of Concor AM?

A: Yes, headache is classified in official documents as a Common adverse reaction. This means it may affect up to 1 in 10 people taking the medicine.

Q: Is Concor AM effective for treating all types of high blood pressure?

A: Official documentation describes the use of the medicine for the management of hypertension (high blood pressure). It is specifically indicated as substitution therapy for adults whose blood pressure is already adequately controlled on the individual components taken separately.

Q: How does Concor AM affect the heart's rhythm?

A: The beta-blocker component (bisoprolol) is documented to cause negative chronotropy, meaning it reduces the heart rate. The medicine is also contraindicated in patients with specific severe atrioventricular (AV) block conditions (a rhythm disturbance).

Q: Can I drive or operate machinery while taking Concor AM?

A: Due to the potential for certain side effects like dizziness, tiredness, or fatigue, regulatory information advises caution regarding the ability to drive or operate heavy machinery, especially when first starting the medicine.

Q: Does Concor AM interact with decongestants or cold medicines?

A: Interactions are documented with certain cold medicines and decongestants that contain sympathomimetic agents (such as pseudoephedrine). These can potentially carry a risk of increasing blood pressure.

Q: If I have a history of depression, is Concor AM safe for me?

A: While depression is listed as an Uncommon adverse reaction, a prior history of depression is not listed as an absolute contraindication in the official product documents.

Q: What happens to the blood sugar levels when taking Concor AM?

A: Caution is noted because the beta-blocker component (bisoprolol) may mask the symptoms of low blood sugar (hypoglycaemia) in patients with diabetes. Bisoprolol is reported to have a generally neutral impact on glucose metabolism.

Storage Conditions

Concor AM tablets must be stored at Controlled Room Temperature, officially defined as 20^circC to 25^circC (68^circF to 77^circF). The medicine must be kept in a closed, light-resistant container and protected from moisture to maintain stability.

Regulatory instructions require that the product be kept from freezing and should not be used if the original container or packaging is compromised. The tablets must be stored out of the sight and reach of children and pets.

---

Disposal Instructions

Unused or expired Concor AM should be discarded promptly and safely. The most appropriate method is typically to utilize an authorized drug take-back program or permanent collection site.

If a take-back option is not available, the tablets must be mixed with an unpalatable substance (like used coffee grounds or dirt), sealed in a plastic bag or container, and discarded in the household trash, following standard government guidelines for non-flushable medicines.